 Over the past few years, antivascular endothelial growth factor, VEGF, therapy has become a standard treatment for neovascular H-related macular degeneration, AMD. During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available antivagent and evidence-based treatment strategies. This article was authored by Jacqueline Alcovac, Stephen G. Shorts, Harry W. Flynn and others.